Catalyst
Slingshot members are tracking this event:
Immunomedics releases Phase 2 study results on IMMU-132, as data show SACITUZUMAB GOVITECAN produces strong response in triple-negative breast cancer patients
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMMU | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 15, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Sacituzumab Govitecan, Triple Negative Breast Cancer, Phase 2, Immu-132
